Protein interactions with platinum–DNA adducts: from structure to function
Authors:
- Stephen G. ChaneySCStephen G. Chaney
- Sharon L. CampbellSCSharon L. Campbell
- Brenda TempleBTBrenda Temple
- Ekaterina BassettEBEkaterina Bassett
- Yibing WuYWYibing Wu
- Mihir FalduMFMihir Faldu
- 1 October 2004
- journal article
- Published by Elsevier in Journal of Inorganic Biochemistry
- Vol. 98 (10) , 1551-1559
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNAJournal of Biological Chemistry, 2002
- Effects of Spectator Ligands on the Specific Recognition of Intrastrand Platinum-DNA Cross-links by High Mobility Group Box and TATA-binding ProteinsJournal of Biological Chemistry, 2001
- Mechanisms of resistance to cisplatinMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001
- Specificity of platinum–DNA adduct repairJournal of Inorganic Biochemistry, 1999
- Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cellsBritish Journal of Cancer, 1999
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panelBiochemical Pharmacology, 1996
- Mutagenic and carcinogenic properties of platinum-based anticancer drugsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1996
- Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell LineJournal of Biological Chemistry, 1996
- Is Cisplatin a Human Carcinogen?JNCI: Journal of the National Cancer Institute, 1992
- OXALIPLATIN < Rec INN >Drugs of the Future, 1989